Published in
American Chemical Society, Journal of Medicinal Chemistry, 24(62), p. 11004-11018, 2019
DOI: 10.1021/acs.jmedchem.9b01295
Links
Tools
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Journal article published in 2019 by
Richard A. Ward 
,
Mark J. Anderton,
Paul Bethel,
Jason Breed,
Calum Cook,
Emma J. Davies,
Andrew Dobson,
Zhiqiang Dong,
Gary Fairley,
Paul Farrington,
Lyman Feron,
Vikki Flemington,
Francis D. Gibbons,
Mark A. Graham,
Ryan Greenwood
and other authors.
,
Mark J. Anderton,
Paul Bethel,
Jason Breed,
Calum Cook,
Emma J. Davies,
Andrew Dobson,
Zhiqiang Dong,
Gary Fairley,
Paul Farrington,
Lyman Feron,
Vikki Flemington,
Francis D. Gibbons,
Mark A. Graham,
Ryan Greenwood
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving allowed
- Must obtain written permission from Editor
- Must not violate ACS ethical Guidelines
Postprint:
archiving restricted
- Must obtain written permission from Editor
- Must not violate ACS ethical Guidelines
Published version:
archiving forbidden
Data provided by 